Recordati Industria Chimica e Farmaceutica

RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE ORDINARY MEETING OF THE SHAREHOLDERS CALLED FOR 29 APRIL 2025

Milan, 8 th April 2025 – With reference to the Ordinary Shareholders' Meeting of Recordati S.p.A. called for 29th April 2025, in a single call, (the "Shareholders' Meeting") please note that, within the terms of law, only one slate composed of no. 10 candidates (the "Slate"), for the appointment of the Board of Directors has been submitted by the shareholder Rossini S.à r.l. ("Rossini"), holder of no. 97,912,463 Recordati's ordinary shares, equal to 46.82% of the share capital.

Please also note that the shareholder Rossini has submitted the following individual resolution proposals on items under the agenda:

determine the number of members of the Board of Directors at 10 (ten) (item 2.a on the agenda);
determine the term of office of the Board of Directors to be appointed at 3 (three) financial years, i.e. until the Shareholders' Meeting called to approve the financial statements as at 31st December 2027 (item 2.b on the agenda).

The Slate, along with the documentation required by law and Bylaws, and the individual resolution proposals submitted by Rossini are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.com - Investors – Shareholder Information section) and on the '' storage mechanism ().

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz +44 7824 394 750 [email protected]

Media Relations

ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected] Gianluca Saletta +39 348 979 4876 [email protected]

UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [email protected]